Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2161-2172

  Longo, Sharon L ^a   Padalino, David J ^a   McGillis, Sandra ^a   Petersen, Kirstin ^c   Schirok, Hartmut ^c   Politz, Oliver ^c   Canute, Gregory W ^a   Post, Dawn E ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

EGFR; Glioma; Her2; Inhibitor; Lapatinib

Indexed keywords

BAY 846; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GLIOMA; HUMANS; MICE; MICE, NUDE; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875543987     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9784-4     Document Type: Article

References (50)

1. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277:301-308
2. Gazdar AF (2010) Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 29:37-48
3. Schneider-Merck T, Trepel M (2010) Lapatinib. Recent Results Cancer Res 184:45-59
4. Moon C, Chae YK, Lee J (2010) Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood) 235:907-920
5. Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME (2009) Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res 7:1000-1012
6. Hynes NE, Macdonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177-184
7. Iyer R, Bharthuar A (2010) A review of erlotinib-an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin Pharmacother 11:311-320
8. Belani CP (2010) The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest 28:413-423
9. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W et al (2009) A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmaco-kinetics and molecular correlation. Cancer Chemother Pharmacol 65:353-361
10. Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J et al (2010) Randomized phase II multicenter trial of two schedules of lapatinib as first-or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 16:1938-1949
11. Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW (2005) Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56:155-162
12. Eller JL, Longo SL, Hicklin DJ, Canute GW (2002) Activity of anti-EGFR monoclonal antibody C225 against glioblastoma multi-forme. Neurosurgery 51:1005-1014
13. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA et al (2007) Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6:1167-1174
14. ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479
15. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK et al (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727-7731
16. Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ (1996) Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 56:3859-3861
17. Cherry T, Longo SL, Tovar-Spinoza Z, Post DE (2010) Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy. Gene Ther 17:1430-1441
18. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM et al (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3:e485
19. Goncalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, Monges G et al (2008) A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 8:169
20. Wiechen K, Karaaslan S, Turzynski A, Dietel M (1999) Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. Br J Cancer 81:790-795
21. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S et al (2005) 2 C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104:2701-2708
22. Szollosi J, Balazs M, Feuerstein BG, Benz CC, Waldman FM (1995) ERBB-2 (HER2/neu) gene copy number, p185HER-2 over-expression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400-5407
23. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980-4986
24. Olayioye MA (2001) Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 3:385-389
25. Fojo T, Parkinson DR (2010) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 16:5972-5980
26. Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, Criniere E et al (2009) Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathol Appl Neurobiol 35:208-213
27. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK et al (2007) The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13:1911-1925
28. Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H et al (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108:135-142
29. Torp SH, Gulati S, Johannessen E, Dalen A (2007) Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An im-munohistochemical study. J Exp Clin Cancer Res 26:353-359
30. Mineo JF, Bordron A, Baroncini M, Maurage CA, Ramirez C, Siminski RM et al (2007) Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85:281-287
31. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068
32. Mineo JF, Bordron A, Quintin-Roué I, Loisel S, Ster KL, Buhé V et al (2004) Recombinant humanised anti-HER2/neu antibody (Herceptin(R)) induces cellular death of glioblastomas. Br J Cancer 91:1195-1199
33. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S et al (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27:3944-3956
34. Quesnelle KM, Grandis JR (2011) Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 17:5935-5944
35. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B (2008) HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 3:e2881
36. Westphal M, Meima L, Szonyi E, Lofgren J, Meissner H, Hamel Wet al (1997) Heregulins and the ErbB-2/3/4 receptors in gliomas. J Neurooncol 35:335-346
37. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639
38. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
39. Boström J, Cobbers JMJL, Wolter M, Tabatabai G, Weber RG, Lichter P et al (1998) Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningio-mas with loss of chromosome arm 10q. Cancer Res 58:29-33
40. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN et al (1998) PTEN mutations in gliomas and glioneuro-nal tumors. Oncogene 16:2259-2264
41. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D et al (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183-4186
42. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND et al (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887
43. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu SJ, Dia EQ et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024
44. Fan QW, Weiss WA (2010) Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 347:279-296
45. Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J et al (2007) Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67:1170-1175
46. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H et al (2010) Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastu-zumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers. J Clin Oncol 29:166-173
47. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Friedecky D, Hajduch M (2010) Lapatinib in breast cancer-the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:281-288
48. Carrasco-Garcia E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, Gomez-Martinez A et al (2011) Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res 317:1476-1489
49. Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6:157-162
50. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092-1103